Predictive Value of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Index on the Oncological Outcomes of Locally Advanced Cervical Cancer Patients

Abstract

Purpose

The oncological outcomes of locally advanced cervical cancer (LACC) patients after treatment are poor and heterogeneous. This study aimed to determine the role of the hemoglobin-albumin-lymphocyte-platelet (HALP) inflammatory index in predicting oncological outcomes in LACC patients.

Patients and Methods

A total of 1588 LACC patients who received radiation therapy or concurrent chemoradiation were divided into training and test sets. Characteristics, survival, and a HALP cutoff determined by X-tile software were used to build predictive survival models on the training data. Validation of the model was performed on both sets.

Results

Patients with a HALP score ≤22.2 tended to have lower age (p < 0.001), lower comorbidity rate (p = 0.016), lower body mass index (p < 0.001), higher stage (p < 0.001), larger tumor size (p < 0.001), and higher likelihood to receive radiation alone than concurrent chemoradiation (p < 0.001). Survival analysis demonstrated that HALP >22.2 was independently associated with better progression-free survival (PFS; hazard ratio; HR 0.55) and overall survival (OS; HR 0.43). Validation of survival prediction by receiver-operating characteristics demonstrated a significantly improved area under the curve of survival prediction in both sets (p < 0.001) after the addition of the HALP index to the model.

Conclusion

A lower HALP score was an independent predictive factor for poorer oncological outcomes. The addition of the HALP index can improve the accuracy of predicting the oncological outcomes of LACC patients.

Introduction

Cervical cancer (CC) is one of the most burdensome malignancies worldwide. Despite the global downward trend owing to the availability of vaccinations and pap smears, the prevalence of CC is still high in many countries, especially in developing regions.¹ In locally advanced CC (LACC), radiation alone (RT) or concurrent chemoradiation (CCRT) is the mainstay treatment,² with a wide survival range of 20.9–71.5%.^3–5 Thus, additional parameters that can help stratify CC oncological outcomes are still desirable.

Following this research in recent years, several novel biomarkers have been discovered, which assist in improved prognosis determination after treatments, such as the squamous cell antigen (SCC-Ag) and HPV-DNA.^6,7 However, these biomarkers have relatively high costs and are not part of a routine examination. Therefore, a combination of pre-treatment laboratory investigations with relatively high accuracy and low cost is still in demand for determining the prognosis of an individual CC patient.

There has been evidence reported on the linkage between inflammation, nutritional status, and cancer progression.^8–11 Chronic inflammation accelerates the release of various cytokines that enhance cancer growth by inhibiting apoptosis and accommodating a neovascularization process leading to cancer progression.⁸ It is also understood that poor nutritional status in cancer patients causes impaired immune function, increased inflammatory response, and leads to increased treatment side effects.^9,10 Additionally, malnutrition status can reflect high tumor metabolic activity since cancer supplies itself with extra energy by taking it from the surrounding environment.¹¹ For this reason, several inflammatory indices have been established to identify the clinical association between inflammation and cancer prognosis, such as C-reactive protein, lactate dehydrogenase, neutrophil-to-lymphocyte ratio (NLR);^12–14 nutritional status indices such as body mass index (BMI) and prognostic nutrition index.^15,16 The hemoglobin-albumin-lymphocyte-platelet (HALP) index is a novel score based on a combination of inflammatory and nutritional deficiency concepts. This index has been found to enhance the prediction accuracy of various cancer prognoses.^17–19 However, there are, to date, no studies on the effect of this index on CC prognoses.

Therefore, this study aimed to examine the prognostic role of the HALP index on oncological outcomes in CC patients who received RT/CCRT treatment. In addition, a predictive model based on the HALP index and other significant parameters was constructed to validate the applicability of this index.

Materials and Methods

Study Selection

This was a retrospective study conducted after approval from the Ethics Committee of the Faculty of Medicine, Prince of Songkla University (REC.64-557-12-1), which waived the requirement for written informed consent due to the retrospective nature of the study. The confidentiality of patient data was guaranteed, as required by the Ethics Committee, and the study was conducted in accordance with the Declaration of Helsinki. CC patients diagnosed from January 2008 to December 2020 who received RT or CCRT at Songklanagarind Hospital were included in the study. The inclusion criteria were as follows: 1 stage IB2-IVA according to the International Federation of Gynecology and Obstetrics (FIGO) 2009 classification, 2 squamous cell carcinoma (SCC), adenocarcinoma (AD), or adenosquamous carcinoma (ASC) histological types, and 3 receiving a platinum chemotherapy regimen for the CCRT group. The exclusion criteria were as follows: 1 receiving neoadjuvant treatment, 2 two primary cancers, 3 inadvertent cancer (accidental diagnosis of cervical cancer after simple hysterectomy for a benign condition), 4 pregnancy, 5) HIV infection, 6 inadequate radiation, and/or 7 incomplete HALP data.

Treatment Protocol

Evaluation before treatment comprised complete physical and pelvic examinations, complete blood count, renal and liver function tests, and serologic tests (HBsAg, VDRL, and HIV status). The radiation protocol consisted of external beam radiation (EBRT) with 6–15 megavolt photon beams with anterior-posterior fields or a four-field box using conventional (2D), 3D conformal RT, occasionally with intensity-modulated radiation therapy (IMRT). The EBRT was delivered to the whole pelvis with lymph node/parametrium/pelvic sidewall boosts of up to 50–60 Gy, divided into 2030 Fr with a rate of 2 Gy/day. Platinum chemotherapy (cisplatin 40 mg/m² or carboplatin AUC 2) was given concurrently once a week during the EBRT. Additionally, 6.5 Gy × 3–4 times of high-dose-rate intracavity brachytherapy was delivered to point A with an Iridium-192 remote after-loading technique during the 3rd to 5th week of treatment. After the treatment, the patients were followed-up according to a protocol as previously described.²⁰

Data Collection

The following characteristics were collected from the hospital database: age, BMI (kg/m²), comorbidities (hypertension, diabetes, dyslipidemia), stage, histological type according to the World Health Organization (WHO) criteria, tumor size, and treatment modality (RT or CCRT). BMI was categorized into 3 groups following a previous study.²¹ For laboratory investigations, pre-treatment hemoglobin (Hb), albumin (Alb), lymphocyte count (Lc), and platelets (Plt) were measured. The HALP index was calculated with the following equation:

\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document} $${\rm{HALP = Hb }}\ \left({{\rm{g/L}}} \right){\rm\ { \times \ Alb }}\ \left({{\rm{g/L}}} \right){\rm{ \ \times \ Lc }}\ \left({{\rm{/L}}} \right){\rm{/Plt }}\ \left({{\rm{/L}}} \right)$$ \end{document} ¹⁸

Oncological outcomes were defined as: 1 progression-free survival (PFS): time since the diagnosis to discovery of disease progression or last follow-up, and 2 overall survival (OS): time from the diagnosis to death or last follow-up. Patients who were lost to follow-up were censored at the last follow-up date.

Statistical Analysis

The whole cohort was split into training (70%) and test (30%) set. All model generation processes were done on the training set only. The optimal HALP cutoff was determined based on PFS by the X-tile program 3.6.1 (Yale University).²² Then, the clinicopathologic characteristics were analyzed according to frequency and percentage, categorized by the HALP cutoff. Univariate survival analysis was performed by constructing a Kaplan–Meier estimate and log-rank analysis. Multivariate analysis was performed using the Cox proportional hazards regression model. The significant p-value was set at ≤0.05. A Receiver Operating Characteristic (ROC) curve was constructed and used to calculate the AUC on both the training and testing sets. The AUC comparison between the models was made using the Wilcoxon rank-sum test. Data analysis in addition to HALP cutoff determination was done using the R program 4.1.2 (R Foundation for Statistical Computing).

Results

Patient Characteristics

Over the 13 years of the recruitment period, a total of 2143 patients were identified according to the inclusion criteria. The excluded cases were as follows: neoadjuvant treatment 52 (2.4%), two primary cancers 55 (2.6%), inadvertent cancer 19 (0.9%), pregnancy 9 (0.4%), HIV infection 77 (3.6%), inadequate treatment 160 (7.5%), and incomplete HALP data 187 (8.7%). Thus, the remaining 1588 patients were eligible for the final analysis. The overall median age of the patients was 52 (interquartile range [IQR] 45–61) years. The median HALP was 34.18 (IQR 21.32–46.8). The cohort was then divided into a training set (70%) and a test set (30%). There were no significant differences in the clinicopathologic characteristics between the two groups after splitting (Table 1).

Table 1.

Clinicopathologic Characteristics of Overall Cohort Divided into Sets

Characteristic	Training Set, N = 1112a	Test Set, N = 476a	p-valueb
Age (years)	52 (44, 61)	52 (46, 61)	0.400
Comorbidities			0.700
No	712 (64%)	300 (63%)
Yes	400 (36%)	176 (37%)
BMI (kg/m2)			0.500
Underweight	61 (5.5%)	33 (6.9%)
Normal	529 (48%)	231 (49%)
Overweight	510 (46%)	212 (45%)
Unknown	12 (1.1%)	0 (0%)
Stage			0.200
I + II	635 (57%)	265 (56%)
III	440 (40%)	186 (39%)
IVA	37 (3.3%)	25 (5.3%)
Histology			>0.900
SCC	893 (80%)	381 (80%)
AD	189 (17%)	81 (17%)
ASC	30 (2.7%)	14 (2.9%)
Tumor size (cm)			0.200
<4	430 (39%)	171 (36%)
4–8	592 (53%)	251 (53%)
>8	38 (3.4%)	24 (5.0%)
Unknown	52 (4.7%)	30 (6.3%)
Modalities			>0.900
RT	121 (11%)	52 (11%)
CCRT	991 (89%)	424 (89%)

Notes: ^aMedian (IQR); n (%). ^bWilcoxon rank sum test; Pearson’s Chi-squared test.

Abbreviations: BMI, body mass index; SCC, squamous cell carcinoma; AD, adenocarcinoma; ASC, adenosquamous carcinoma; RT, radiation alone; CCRT, concurrent chemoradiation.

Establishment of HALP Cutoff

The optimal cut-point was 22.2 following X-tile’s two categorical variables chi-square test from the training data (Figure 1). Then, the patients were divided into ≤22.2 and >22.2 groups. The clinicopathologic characteristics according to the HALP index showed that patients with HALP ≤22.2 tended to have lower age (p < 0.001), lower comorbidity rate (p = 0.016), lower BMI (p < 0.001), higher stage (p < 0.001), larger tumor size (p < 0.001), and were more likely to receive RT than CCRT (p < 0.001). However, the difference in histological type between the HALP categories was not significant (Table 2).

Figure 1.

HALP index cut point determination by X-tile program: (A) HALP histogram (B) Cut-point value.

Table 2.

Characteristics According to HALP Group in Training Data

Characteristic	≤22.2, N = 289a	>22.2, N = 823a	p-valueb
Age (years)			<0.001
<50	146 (51%)	319 (39%)
≥50	143 (49%)	504 (61%)
Comorbidities			0.016
No	202 (70%)	510 (62%)
Yes	87 (30%)	313 (38%)
BMI (kg/m2)			<0.001
Underweight	27 (9.3%)	34 (4.1%)
Normal	155 (54%)	374 (45%)
Overweight	100 (35%)	410 (50%)
Unknown	7 (2.4%)	5 (0.6%)
Stage			<0.001
I + II	104 (36%)	531 (65%)
III	155 (54%)	285 (35%)
IVA	30 (10%)	7 (0.9%)
Histology			0.300
SCC	240 (83%)	653 (79%)
AD	41 (14%)	148 (18%)
ASC	8 (2.8%)	22 (2.7%)
Tumor size (cm)			<0.001
<4	53 (18%)	377 (46%)
4–8	196 (68%)	396 (48%)
>8	24 (8.3%)	14 (1.7%)
Unknown	16 (5.5%)	36 (4.4%)
Modalities			<0.001
RT	61 (21%)	60 (7.3%)
CCRT	228 (79%)	763 (93%)

Note: ^an (%). ^bPearson’s Chi-squared test.

Abbreviations: BMI, body mass index; SCC, squamous cell carcinoma; AD, adenocarcinoma; ASC, adenosquamous carcinoma; RT, radiation alone; CCRT, concurrent chemoradiation.

Survival Analysis

The median follow-up time was 2.96 (IQR1.39–5.47) years. From all patients, 456 cases (28.71%) had tumor recurrence. The 5-year PFS and 5-year OS of all patients were 65% (95% confidence interval [CI] 0.63–0.68) and 87.5% (95% CI 0.86–0.90). The univariate analysis in the training set (Table 3) demonstrated that the significant factors associated with worse PFS were HALP ≤22.2 (p < 0.001; Figure 2A), lower BMI (p = 0.01), higher stage (p < 0.001), non-SCC histology (p = 0.007), larger tumor size (p < 0.001), and RT (p < 0.001), while the important factors associated with worse OS were HALP ≤ 22.2 (p < 0.001; Figure 2B), higher stage (p < 0.001), larger tumor size (p < 0.001), and RT (p < 0.001).

Table 3.

Univariate Analysis of Factors Associated with Altered PFS and OS on Training Data

Characteristic	PFS		OS
	5-year PFS (95% CI)	p-valuea	5-year OS (95% CI)	p-valuea
HALP cutoff		<0.001		<0.001
≤22.2	46% (39–54%)		77% (71–84%)
>22.2	71% (68–75%)		92% (90–95%)
Age (years)		0.200		0.800
<50	63% (58–68%)		89% (86–92%)
≥50	66% (62–71%)		89% (86–92%)
Comorbidities		>0.900		0.200
No	65% (62–70%)		90% (88–93%)
Yes	64% (58–70%)		87% (83–91%)
BMI (kg/m2)		0.010		0.400
Underweight	53% (41–70%)		87% (78–97%)
Normal	63% (58–68%)		88% (85–91%)
Overweight	69% (65–74%)		91% (88–94%)
Stage		<0.001		<0.001
I + II	76% (72–80%)		94% (92–96%)
III	51% (46–58%)		83% (79–88%)
IVA	23% (10–49%)		53% (37–76%)
Histology		0.007		0.500
SCC	68% (64–71%)		89% (86–91%)
AD	57% (49–66%)		88% (82–94%)
ASC	47% (31–73%)		96% (88–100%)
Tumor size (cm)		<0.001		<0.001
<4	74% (69–79%)		95% (92–97%)
4–8	58% (54–63%)		86% (82–89%)
>8	44% (27–70%)		81% (68–96%)
Modalities		<0.001		<0.001
RT	43% (34–55%)		76% (67–87%)
CCRT	68% (64–71%)		90% (88–92%)

Note: ^aLog rank test.

Abbreviations: CI, confidence Interval; BMI, body mass index; SCC, squamous cell carcinoma; AD, adenocarcinoma; ASC, adenosquamous carcinoma; RT, radiation alone; CCRT, concurrent chemoradiation.

Figure 2.

Kaplan-Meier analysis of HALP according to HALP cut-point: (A) Progression-free survival (B) Overall survival.

Further multivariate analysis showed that HALP index (>22.2 vs ≤22.2; hazard ratio [HR] 0.55; 95% CI 0.43–0.70), stage (III vs I+II; HR 1.88; 95% CI 1.46–2.42 and IVA vs I+II; HR 5.18; 95% CI 3.18–8.44), histology (AD vs SCC; HR 1.74; 95% CI 1.32–2.31 and ASC vs SCC; HR 1.79; 95% CI 1.02–3.13), tumor size (>8 vs <4 cm; HR 1.90; 95% CI 1.12–3.24), and treatment modality (CCRT vs RT; HR 0.55; 95% CI 0.41–0.75) were independently associated with worse PFS, while only HALP cut off (>22.2 vs ≤22.2; HR 0.43; 95% CI 0.27–0.67), stage (III vs I+II; HR 1.96; 95% CI 1.22–31.7 and IVA vs I+II; HR 5.45; 95% CI 2.58–11.50), and treatment modality (CCRT vs RT; HR 0.38; 95% CI 0.21–0.67) were independently associated with worse OS (Table 4). We also tested for the time-varying effect of HALP and found that the detrimental effect of HALP ≤22.2 on both PFS and OS diminished after more than 5 years and 3 years survival, respectively (data not shown).

Table 4.

Multivariate Analysis of Factors Associated with Altered PFS and OS on Training Data

Characteristic	PFS			OS
	HR	95% CI	p-value	HR	95% CI	p-value
HALP cutoff
≤22.2	1.00	—		1.00	—
>22.2	0.55	0.43–0.70	<0.001	0.43	0.27–0.67	<0.001
Stage
I + II	1.00	—		1.00	—
III	1.88	1.46–2.42	<0.001	2.02	1.25–3.25	0.004
IVA	5.18	3.18–8.44	<0.001	5.81	2.75–12.3	<0.001
Histology
SCC	1.00	—		1.00	—
AD	1.74	1.32–2.31	<0.001	1.18	0.67–2.07	0.600
ASC	1.79	1.02–3.13	0.043	0.38	0.05–2.72	0.300
Tumor size (cm)
<4	1.00	—		1.00	—
4–8	1.30	1.00–1.69	0.052	1.58	0.93–2.67	0.091
>8	1.90	1.12–3.24	0.018	2.14	0.84–5.49	0.110
Modalities
RT	1.00	—		1.00	—
CCRT	0.55	0.41–0.75	<0.001	0.56	0.33–0.95	0.030

Abbreviations: HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; AD, adenocarcinoma; ASC, adenosquamous carcinoma; RT, radiation alone; CCRT, concurrent chemoradiation.

Construction of the Predictive Survival Model

To further investigate the predictive power of the HALP index on survival, ROC analysis of PFS and OS prediction was performed based on two constructed Cox’s hazard regression models (Figures 3 and 4): 1 independently significant factors from multivariate analysis (Table 4) without HALP and 2 independently significant factors from multivariate analysis with HALP. The results demonstrated that the addition of HALP to the model improved the AUCs for prediction of PFS at 1, 3, and 5 years from 0.70, 0.71, and 0.71 to 0.73, 0.73, and 0.72 in the training set (p < 0.001) and from 0.66, 0.66, and 0.69 to 0.71, 0.69, and 0.71 in the test set (p < 0.001), respectively (Figure 5). The AUCs for prediction of OS also improved from 0.73, 0.68, and 0.70 to 0.79, 0.70, and 0.72 in the training set (p < 0.001) and 0.64, 0.60, and 0.63 to 0.72, 0.69, and 0.72 in the test set (p < 0.001), respectively (Figure 6). We also created an interactive web application (https://hgatc.psu.ac.th/halp/ or https://github.com/LKittinun/HALP_survival_model) generated from the formula:

Figure 3.

Predictive accuracy of HALP model on progression-free survival in both sets.

Figure 4.

Predictive accuracy of HALP model on overall survival in both sets.

Figure 5.

Spot predictive accuracy of HALP model on progression-free survival (PFS) in both sets: (A) 1-year PFS (B) 3-year PFS (C) 5-year PFS.

Figure 6.

Spot predictive accuracy of HALP model on overall survival (OS) in both sets: (A) 1-year OS (B) 3-year OS (C) 5-year OS.

log(HR_PFS) = 0.40−0.60(HALP > 22.2)+0.63(stage III)+1.64(stage IVA)+0.56(AD)+

0.58(ASC)−0.59(CCRT)+0.26(tsize = 4–8)+0.64(tsize > 8)

log(HR_OS) = 0.82−0.96(HALP > 22.2)+0.71(stage III)+1.89(stage IVA)−0.52(CCRT).

Discussion

To date, many hematologic indices or parameters have been proposed to help determine the prognosis of cancers.^12–16 However, combinations of commonly used pre-treatment investigations, such as NLR, platelet-to-lymphocyte ratio (PLR), and HALP, that can help determine a patient’s prognosis at no additional cost, are still worth exploring. Among the other indices in this category, HALP has been proposed as the best prognosis predictor among the hematologic parameters in some cancers.^23,24 For example, a study by Cong et al found that compared with NLR and PLR, only HALP was an independent significant prognostic factor among all indices of esophageal carcinoma.²³ Another study was from Guo et al, which compared the AUCs of HALP, NLR, and PLR for the prognosis of metastatic prostate cancer. The study found that HALP and its variant had the highest AUC compared with the others.²⁴ For this reason, HALP is one of the most interesting indices to be explored at this moment.

To our knowledge, our study is the first study to demonstrate that the association of HALP on oncological outcomes can be applied to LACC patients. Our study demonstrated that a HALP score ≤22.2 was associated with higher stage and tumor size in the CC cohort. This result was in line with studies of other cancers in which at least one feature of a more advanced stage or larger tumor size was present in the low HALP group.^17,25–28 In the context of survival, our study found that a HALP score ≤22.2 was independently associated with worse PFS and OS. This result was in concordance with several other studies that demonstrated an impact of lower HALP on poorer prognosis for several cancers, such as bladder, colorectal, gastric, prostate, esophageal, and lung cancers, with varying cut-points depending on the cancer type and study setting.^{17–19,23,24,29,30} Additionally, we found that the deleterious effect of a low HALP diminished when the patient survived for a particular time.

Several mechanisms can explain the impact of inflammation and nutrition status on the HALP index and CC prognosis. In a chronic inflammatory state, various cytokines in the body become altered, such as NF-κB, p53, HIF-α, and VEGF. The alteration of these cytokines has been reported to dysregulate cancer apoptosis inhibition and promote neovascularization, leading to more advanced stages of CC.⁸ In addition, inflammation causes shortened erythrocyte survival, suppressed bone marrow function, and hypoferremia, resulting in low hemoglobin levels.³¹ Supporting evidence from earlier studies showed that a hemoglobin level <10 g/dL had a negative impact on CC radiation outcome, whereby the impaired DNA damage process is from insufficient oxygenation of tumor tissue.^32,33 Conversely, some inflammatory cytokines, such as thrombopoietin and IL-6, stimulate platelet production, a condition known as reactive thrombocytosis, which has been shown to be associated with poor CC survival.^34,35 Also, malnutrition is associated with low albumin and lymphocyte quantity since essential substrates required for production are limited by these conditions.³⁶ Accordingly, cancer patients are prone to malnutrition due to the ability of cancers to shift adjacent cells from normal conditions to generate lactate via glycolysis for them, resulting in energy leaching from cells to tumors, a process termed the reverse Warburg effect. This catabolite transfer is thought to damage the surrounding normal tissues and favor the invasion and metastasis of cancer.³⁷

To validate the generalizable effect of HALP on oncological outcomes, we constructed multiple predictive models based on a training set and validated on a test set. We discovered that besides other known associated factors, such as stage, histology, and treatment modality, the addition of the HALP index to the model significantly improved the model’s predictive accuracy for both sets. This method resulted in findings similar to several previously published papers, such as a study by Jiang et al,¹⁸ which created a survival model for colorectal cancer patients using a training set and validation set and obtained competent AUCs at 0.73 and 0.74. Likewise, a study by Sun et al³⁸ found an improvement in the prediction model after incorporating HALP with other known variables, such as operation outcome and TNM staging (C-index 0.66 vs 0.63).

The strength of our study is that a large number of patients were recruited over a long period. However, some limitations have to be addressed. First, some incomplete and/or missing documentation could not be avoided due to the retrospective nature of the study. Second, all patients were recruited from a single center. Therefore, the setting of the study has to be taken into account when interpreting the result for clinical use. Finally, some potential confounders that can influence LACC oncological outcomes were not available. For these reasons, further large-scale multicenter studies with standardized patient conditions are necessary to confirm our findings.

In conclusion, our study found that a lower HALP was associated with higher stage and larger tumor size and was also an independent factor for poorer oncological outcomes. The addition of a HALP index can improve the accuracy of determining oncological outcomes of LACC patients. These results suggest that the HALP index may be useful as a clinical prognostic factor for LACC patients after receiving RT/CCRT treatment.

Disclosure

The authors report no conflicts of interest in this work.